Joshua Liang

Oversee company operations & strategy; since joining Clover in 2016, raised over RMB 750 million (~US$100 million) in total capital, grew FTE headcount 6x to nearly 200 by early 2020, initiated Clover's first clinical trials in Australia & China and led immuno-oncology R&D programs.

Former investment banker at Centerview Partners in the healthcare advisory practice, primarily focused in the life sciences sector